Development of highly efficient nanocarrier-mediated delivery approaches for cancer therapy

Keunsoo Jeong, Chi Soo Kang, Youngsun Kim, Yong Deok Lee, Ick Chan Kwon, Sehoon Kim

    Research output: Contribution to journalReview articlepeer-review

    61 Citations (Scopus)

    Abstract

    Nanocarriers (NCs) are a group of nano-sized vehicles devised to deliver drugs to targeted malignant tissues or organs that provide remarkably improved targeting efficiency and therapeutic efficacy for cancer therapy. A variety of NCs have been developed to accommodate appropriate loading and release of drugs with a wide spectrum of chemical and physical characteristics. In addition, physicochemical modifications to the surface or interior of NCs allow for modulation of pharmacokinetic features reflecting clinical demands. However, cancer-related mortality is still high and drug-mediated cancer treatment remains a challenging research field despite the remarkable advances in targeting efficiency and therapeutic efficacy resulting from NCs. In this review, we focus on typical approaches and recent trends in NC-mediated drug delivery systems and their potential for targeted cancer therapy.

    Original languageEnglish
    Pages (from-to)31-43
    Number of pages13
    JournalCancer letters
    Volume374
    Issue number1
    DOIs
    Publication statusPublished - 2016 Apr 28

    Bibliographical note

    Funding Information:
    This work was supported by the grants from the National Research Foundation of Korea (No. 2014M3A9E5073316 , 2014M3C1A3054141 ), the Korea Health Industry Development Institute (No. HI15C1540 ), and the Intramural Research Program of KIST .

    Publisher Copyright:
    © 2016 Elsevier Ireland Ltd.

    Keywords

    • Cancer therapy
    • Combination therapy
    • Drug delivery
    • Nanocarrier
    • Stimuli-activated therapy

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'Development of highly efficient nanocarrier-mediated delivery approaches for cancer therapy'. Together they form a unique fingerprint.

    Cite this